The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Open accessAbstract
BACKGROUND: Patients with hemophilia A rely on exogenous factor VIII to prevent bleeding in joints, soft tissue, and the central nervous system. Although successful gene transfer has been reported in patients with hemophilia B, the large size of the factor VIII coding region has precluded improved outcomes with gene therapy in patients with hemophilia A. METHODS: We infused a single intravenous dose of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5-hFVIII-SQ) in nine men with severe hemophilia A. Participants were enrolled sequentially into one of three dose cohorts (low dose [one participant], intermediate dose [one participant], and high dose [seven participants]) and were followed through 52 weeks. RESULTS: Factor VIII activity levels remained at 3 IU or less per deciliter in the recipients of the low or intermediate dose. In the high-dose cohort, the factor VIII activity level was more than 5 IU per deciliter between weeks 2 and 9 after gene transfer in all seven participants, and the level in six participants increased to a normal value (>50 IU per deciliter) that was maintained at 1 year after receipt of the dose. In the high-dose cohort, the median annualized bleeding rate among participants who had previously received prophylactic therapy decreased from 16 events before the study to 1 event after gene transfer, and factor VIII use for participant-reported bleeding ceased in all the participants in this cohort by week 22. The primary adverse event was an elevation in the serum alanine aminotransferase level to 1.5 times the upper limit of the normal range or less. Progression of preexisting chronic arthropathy in one participant was the only serious adverse event. No neutralizing antibodies to factor VIII were detected. CONCLUSIONS: The infusion of AAV5-hFVIII-SQ was associated with the sustained normalization of factor VIII activity level over a period of 1 year in six of seven participants who received a high dose, with stabilization of hemostasis and a profound reduction in factor VIII use in all seven participants. In this small study, no safety events were noted, but no safety conclusions can be drawn. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795 ; EudraCT number, 2014-003880-38 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both transgene products, FVIII-SQ and FIX-R338L, demonstrate variable activity measurements in OSA versus chromogenic assay (CSA) determinants of factor activity that are reproducible across trials.144,145,149,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [149]
In the citing paper
“multiple HA and HB trials have demonstrated ≥10-fold variability in FVIII:C/FIX:C with the same vector and dose (Harrington et al., 2020, WFH Virtual Summit, conference).145,149,150,153”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [149]
In the citing paper
“Corticosteroids are the most commonly used agents to resolve transaminitis, however, its relationship with resolution by corticosteroids and T-cell response are not always clear as observed in a hemophilia A trial (28, 105).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [28]
In the citing paper
“clinical gene therapy using a codon-optimized exogenous construct to compensate for mutations in a nuclear gene (e.g. hemophilia, [69]) is ongoing”
From Codon optimization is an essential parameter for the efficient allotopic expression of mtDNA genes (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinás, A. M., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,949
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H. Z., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 682
Flagged first, then by citations
Research works printed but not linked: 1
- Falese L, Gene Ther
Cited by
Sorted by citations
Items 301–400 of 692
Minno, A. D., Spadarella, G., Nardone, A., Mormile, M., Ventre, I., Morfini, M., & Minno, G. D. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.08.003 · Cited by 18
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025
Pierce, G. F., Ozelo, M. C., Mahlangu, J. N., Dunn, A. L., Beijlevelt, M., Bender, R., Carcao, M. D., Coffin, D., Grazzi, E. F., Foster, G. R., et al. (2025) · Haemophilia · doi:10.1111/hae.70113 · Cited by 17
Self-citationGhanem, R., Laurent, V., Roquefort, P., Haute, T., Ramel, S., Gall, T. L., Aubry, T., & Montier, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010047 · Cited by 19
Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy
Boban, A., Baghaei, F., Fijnvandraat, K., Klamroth, R., Miesbach, W., Stephensen, D., Kavanagh, M., Noone, D., Crato, M., & Peyvandi, F. (2023) · Haemophilia · doi:10.1111/hae.14887 · Cited by 17
Optimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques
Greig, J. A., Nordin, J. M. L., White, J. W., Wang, Q., Bote, E., Goode, T. L., Calcedo, R., Wadsworth, S. C., Wang, L., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.080 · Cited by 17
Tolerance induction in hemophilia: innovation and accomplishments
Sherman, A., Biswas, M., & Herzog, R. W. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000446 · Cited by 17
Variable readthrough responsiveness of nonsense mutations in hemophilia A
Martorell, L., Cortina, V., Parra, R., Barquinero, J., & Vidal, F. (2019) · Haematologica · doi:10.3324/haematol.2018.212118 · Cited by 17
Guen, Y. T. L., Gall, T. L., Midoux, P., Guégan, P., Braun, S., & Montier, T. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3150 · Cited by 18
Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
El-Akabawy, N., Rodriguez, M., Ramamurthy, R. M., Rabah, A., Trevisan, B., Morsi, A., George, S. K., Shields, J. E., Meares, D., Farland, A. M., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.001 · Cited by 17
Vasquez-Loarte, T. C., Lucas, T. L., Harris-Wai, J. N., & Bowen, D. J. (2020) · Patient · doi:10.1007/s40271-020-00442-7 · Cited by 17
A narrative review of in utero gene therapy: advances, challenges, and future considerations
Yung, N. K., Maassel, N. L., Ullrich, S. J., Ricciardi, A. S., & Stitelman, D. H. (2021) · Translational Pediatrics · doi:10.21037/tp-20-89 · Cited by 17
Elkouby, L., Armour, S. M., Toso, R., DiPietro, M. A., Davidson, R. J., Nguyen, G. N., Willet, M., Kutza, S., Silverberg, J., Frick, J. E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.005 · Cited by 18
Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice
Song, S., Lyle, M. J., Noble-Vranish, M. L., Tran, D. M., Harrang, J., Xiao, W., Unger, E. C., & Miao, C. H. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.006 · Cited by 17
Evolving Complexity in Hemophilia Management
Croteau, S. E. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.01.004 · Cited by 17
Experimental gene therapies for the NCLs
Liu, W., Holthaus, S.-M. K., Herranz-Martín, S., Aristorena, M., Mole, S., Smith, A. J., Ali, R. R., & Rahim, A. A. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165772 · Cited by 18
Maurizi, N., Ammirati, E., Silver, E., Hong, K., Bui, Q. M., Argirò, A., Olivotto, I., & Adler, E. D. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.004 · Cited by 16
Gene Therapy: Paving New Roads in the Treatment of Hemophilia
Yamaguti-Hayakawa, G. G., & Ozelo, M. C. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1688445 · Cited by 16
Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
Mével, M., Pichard, V., Bouzelha, M., Álvarez‐Dorta, D., Lalys, P.-A., Provost, N., Allais, M., Mendes, A., Landagaray, E., Ducloyer, J., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101187 · Cited by 16
Prevention and Management of Bleeding Episodes in Children with Hemophilia
Ljung, R. C. R. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0307-z · Cited by 16
Homozygous familial hypercholesterolemia: what treatments are on the horizon?
Bajaj, A., & Cuchel, M. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000677 · Cited by 17
Spadarella, G., Minno, A. D., Brunetti‐Pierri, N., Mahlangu, J. N., & Minno, G. D. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100737 · Cited by 16
Liver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
Chen, A. C., Cai, X., Li, C., Khoryati, L., Gavin, M. A., & Miao, C. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00638 · Cited by 16
Hemophilia as a blueprint for gene therapy
Ragni, M. V. (2021) · Science · doi:10.1126/science.abg0856 · Cited by 16
Watano, R., Ohmori, T., Hishikawa, S., Sakata, A., & Mizukami, H. (2020) · Gene Therapy · doi:10.1038/s41434-020-0125-0 · Cited by 16
Zhukouskaya, V. V., Jauze, L., Charles, S., Leborgne, C., Hilliquin, S., Sadoine, J., Slimani, L., Baroukh, B., van Wittenberghe, L., Danièle, N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5018 · Cited by 15
Zou, P. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00555 · Cited by 15
Sharma, A., Mathew, M. E., Sriganesh, V., & Reiss, U. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010822.pub3 · Cited by 15
Dougherty, J. A., & Dougherty, K. M. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231202247 · Cited by 16
Mura, V. L., Cardinale, V., CRISTOFARO, R. D., Santis, A. D., Minno, G. D., Fabris, L., Marra, F., Morisco, F., Peyvandi, F., Pompili, M., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013750 · Cited by 15
Gene therapy in hemophilia: the dawn of a new era
Gualtierotti, R., Giachi, A., Bitto, N., Mura, V. L., & Peyvandi, F. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102640 · Cited by 14
Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy
Piccolo, P., & Brunetti‐Pierri, N. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.179 · Cited by 15
Gene therapies for hemophilia hit the mark in clinical trials
Pickar, A., & Gersbach, C. A. (2018) · Nature Medicine · doi:10.1038/nm.4492 · Cited by 14
Thompson, W. S., Mondal, G., VanLith, C. J., Kaiser, R. A., & Lillegard, J. B. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1791082 · Cited by 15
Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A
Gong, J., Chung, T., Zheng, J., Zheng, H., & Chang, L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101397 · Cited by 14
Health technology assessment for gene therapies in haemophilia
O’Hara, J., & Neumann, P. J. (2022) · Haemophilia · doi:10.1111/hae.14413 · Cited by 14
Liu, S., Razon, L., Ritchie, O., Sihn, C., Handyside, B., Berguig, G. Y., Woloszynek, J. R., Zhang, L., Batty, P. A., Lillicrap, D., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.05.008 · Cited by 15
Gene therapy for hemophilia: looking beyond factor expression
Yamaguti-Hayakawa, G. G., & Ozelo, M. C. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221147565 · Cited by 14
Gene therapy for hemophilia, a clinical viewpoint
Chou, S., Hsu, Y., & Lin, S. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.05.008 · Cited by 15
Hosaka, T., Tsuji, H., & Kwak, S. (2023) · Cells · doi:10.3390/cells12101443 · Cited by 14
Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment
Chandran, R., Tohit, E. R. M., Stanslas, J., Salim, N., Mahmood, T. M. T., & Rajagopal, M. S. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1778103 · Cited by 14
Bioengineered molecules for the management of haemophilia: Promise and remaining challenges
Pipe, S. W. (2018) · Haemophilia · doi:10.1111/hae.13507 · Cited by 14
Haemophilia, the journey in search of a cure. 1960–2020
Nathwani, A. C., & Tuddenham, E. G. D. (2020) · British Journal of Haematology · doi:10.1111/bjh.17155 · Cited by 14
A Cure for Hemophilia within Reach
van den Berg, H. M. (2017) · New England Journal of Medicine · doi:10.1056/nejme1713888 · Cited by 14
Adeno-Associated Virus Delivery Limitations for Neurological Indications
Benatti, H. R., & Gray‐Edwards, H. L. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29196.hrb · Cited by 14
Kistner, A., Chichester, J. A., Wang, L., Calcedo, R., Greig, J. A., Cardwell, L. N., Wright, M. C., Couthouis, J., Sethi, S., McIntosh, B. E., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00423-z · Cited by 13
Ling, G., & Tuddenham, E. G. D. (2020) · British Journal of Haematology · doi:10.1111/bjh.16311 · Cited by 13
El‐Maarri, O., Jamil, M. A., & Oldenburg, J. (2020) · Hämostaseologie · doi:10.1055/a-1282-2286 · Cited by 13
Qiu, L., Xie, M., Zhou, M., Liu, X., Hu, Z., & Wu, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630353 · Cited by 13
Gene therapy – are we ready now?
Kaczmarek, R. (2022) · Haemophilia · doi:10.1111/hae.14530 · Cited by 14
Emerging therapeutic potential of adeno-associated virus-mediated gene therapy in liver fibrosis
Bu, F., Jia, P., Zhu, Y. Y., Yang, Y., Meng, H., Bi, Y., Huang, C., & Li, J. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.06.009 · Cited by 14
Valoctocogene roxaparvovec gene transfer in participants with HIV
Ragni, M. V., Majerus, E. M., Fong, S., Yates, B., Scheeler, S., Razon, L., Yu, H. J., Reddy, D. B., & Robinson, T. M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008948 · Cited by 13
Self-citationMuñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
Novel Lung Tropic Adeno-Associated Virus Capsids for Therapeutic Gene Delivery
Carneiro, A. D., Lee, H., Lin, L. W., van Haasteren, J., & Schaffer, D. V. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.169 · Cited by 13
Reimbursing the value of gene therapy care in an era of uncertainty
Noone, D., Coffin, D., & Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14218 · Cited by 13
Self-citationPlatelet-targeted gene therapy induces immune tolerance in hemophilia and beyond
Kumar, S., Schroeder, J. A., & Shi, Q. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.07.025 · Cited by 12
Castaman, G., Coppens, M., & Pipe, S. W. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2276206 · Cited by 12
Han, Z., Yi, X., Li, J., Liao, D., Gao, G., & Ai, J. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.208 · Cited by 12
Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives
Bala, N. S., & Thornburg, C. D. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1785483 · Cited by 12
Perioperative Management of Hemophilia Patients
Lowell, A. E., Calgi, M. P., Caruso, J. J., Man, L. M.-W., & McNeil, J. S. (2024) · Current anesthesiology reports · doi:10.1007/s40140-024-00635-y · Cited by 12
Konkle, B. A., Peyvandi, F., Foster, G. R., Hermans, C. R. J. R., Mura, V. L., Leavitt, A. D., Lillicrap, D., Mahlangu, J. N., Ozelo, M. C., Pipe, S. W., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.02.042 · Cited by 12
Escape or Fight: Inhibitors in Hemophilia A
Merlin, S., & Follenzi, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00476 · Cited by 13
Redefining prophylaxis in the modern era
Mahlangu, J. N., Blanchette, V. S., & Klamroth, R. (2020) · Haemophilia · doi:10.1111/hae.14035 · Cited by 12
Utilization of a novel Sendai virus vector in ex vivo gene therapy for hemophilia A
Yamaki, Y., Fukushima, T., Yoshida, N., Nishimura, K., Fukuda, A., Hisatake, K., Aso, M., Sakasai, T., Kijima-Tanaka, J., Miwa, Y., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-020-03059-6 · Cited by 12
Development of an Adeno-Associated Virus-Vectored SARS-CoV-2 Vaccine and Its Immunogenicity in Mice
Qin, X., Li, S., Li, X., Pei, D., Liu, Y., Ding, Y., Liu, L., Bi, H., Shi, X., Guo, Y., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.802147 · Cited by 12
Zhang, T., Yang, Y., Liu, Y., Zhang, T., & Yang, N. (2022) · Shock · doi:10.1097/shk.0000000000002000 · Cited by 12
Expectation and loss when gene therapy for haemophilia is not an option: An exigency sub‐study
Fletcher, S. J., Jenner, K., Holland, M., & Khair, K. (2023) · Haemophilia · doi:10.1111/hae.14774 · Cited by 12
Korte, W. C., & Graf, L. (2018) · Transfusion Medicine and Hemotherapy · doi:10.1159/000488152 · Cited by 12
Future AAVenues for In Utero Gene Therapy
MacKenzie, T. C. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.08.010 · Cited by 12
Shi, Q., Mattson, J. G., Fahs, S. A., Geurts, A. M., Weiler-Guettler, H., & Montgomery, R. R. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000944 · Cited by 12
The Evolution of Gene Therapy in the Treatment of Metabolic Liver Diseases
Moscoso, C. G., & Steer, C. J. (2020) · Genes · doi:10.3390/genes11080915 · Cited by 12
Nair, N., Wolf, D. D., Nguyen, P. A., Pham, Q. H., Samara-Kuko, E., Landau, J., Blouse, G. E., Chuah, M., & VandenDriessche, T. (2021) · Blood · doi:10.1182/blood.2020006005 · Cited by 13
Agboola, F. O., Rind, D. M., Walton, S. M., Herron-Smith, S., Quach, D., & Pearson, S. D. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.5.667 · Cited by 12
Hemophilia: The Past, the Present, and the Future
Matuk-Villazon, O., Roberts, J. C., & Corrales‐Medina, F. F. (2021) · Pediatrics in Review · doi:10.1542/pir.2020-004143 · Cited by 12
Minno, G. D., Miesbach, W., Castaman, G., & Peyvandi, F. (2024) · Haematologica · doi:10.3324/haematol.2023.284622 · Cited by 13
Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care
Dushimova, Z., Орумбасарович, П. М., Kaibullayeva, J. A., Danyarova, L., Kultanova, E., Abdilova, G., & Mustapayeva, N. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618464 · Cited by 11
Role of Essential Metal Ions in AAV Vector-Mediated Transduction
Rambhai, H. K., Ashby, F. J., Qing, K., & Srivastava, A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.019 · Cited by 11
Gene therapy: An updated overview on the promising success stories.
Rashid, R. A., & Ankathil, R. (2020) · PubMed · Cited by 11
Therapeutic management of hereditary angioedema: past, present, and future
Valerieva, A., Nedeva, D., Yordanova, V., Petkova, E., & Staevska, M. T. (2021) · Balkan Medical Journal · doi:10.5152/balkanmedj.2021.21094 · Cited by 11
Transhumanist Genetic Enhancement: Creation of a ‘New Man’ Through Technological Innovation
Mendz, G. L., & Cook, M. (2021) · The New Bioethics · doi:10.1080/20502877.2021.1917228 · Cited by 12
Katz, M. G., Hadas, Y., Bailey, R. A., Fazal, S., Vincek, A. S., Madjarova, S. J., Shtraizent, N., Vandenberghe, L. H., & Eliyahu, E. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.05.050 · Cited by 11
Barbon, S., Stocco, E., Rajendran, S., Zardo, L., Macchi, V., Grandi, C., Tagariello, G., Porzionato, A., Radossi, P., De, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137282 · Cited by 11
Gene therapy in haemophilia: literature review and regional perspectives for Turkey
Kavaklı, K., Antmen, B., Okan, V., Şahin, F., Aytaç, S., Balkan, C., Berber, E., Kaya, Z., Küpesiz, A., & Zülfikar, B. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221104591 · Cited by 11
Novel Gene-Correction-Based Therapeutic Modalities for Monogenic Liver Disorders
Ghasemzad, M., Hashemi, M., Miri-Lavasani, Z., Hossein‐Khannazer, N., Bakhshandeh, H., Gramignoli, R., Alikhani, H. K., Najimi, M., Nikeghbalian, S., & Vosough, M. (2022) · Bioengineering · doi:10.3390/bioengineering9080392 · Cited by 11
Minno, G. D., Castaman, G., CRISTOFARO, R. D., Brunetti‐Pierri, N., Pastore, L., Castaldo, G., Trama, U., & Minno, M. N. D. D. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101011 · Cited by 11
RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes
Subramanian, M. P., McIninch, J., Zlatev, I., Schlegel, M. K., Kaittanis, C., Nguyen, T. M., Agarwal, S., Racie, T., Alvarado, M. A., Wassarman, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37774-5 · Cited by 11
Astermark, J., Buckner, T. W., Frenzel, L., Hatswell, A. J., You, X., Liu, H., Goodman, E., Santos, S., Hawes, C. R., Hinds, D. R., et al. (2023) · Haemophilia · doi:10.1111/hae.14818 · Cited by 11
Ohmori, T., Mizukami, H., Katakai, Y., Kawai, S., Nakamura, H., Inoue, M., Shu, T., Sugimoto, H., & Sakata, Y. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2465-8 · Cited by 11
Zhang, L., Handyside, B., Murphy, R., Sihn, C., Xie, L. Y., Vitelli, C., Harmon, D., Sisó, S., Liu, S., Bullens, S., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.007 · Cited by 11
Jin, Q., Qiao, C., Li, J., Li, J., & Xiao, X. (2019) · Gene Therapy · doi:10.1038/s41434-019-0107-2 · Cited by 11
Advances in Hemophilia A Management
Cho, S., Perry, A. M., Cheng, A. M., Wang, C., & Rico, J. F. (2022) · Advances in Pediatrics · doi:10.1016/j.yapd.2022.03.009 · Cited by 11
van Overbeeke, E., Hauber, B., Michelsen, S., Goldman, M., Simoens, S., & Huys, I. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.595797 · Cited by 11
Current and Future Options of Haemophilia A Treatments
Miesbach, W., & Eladly, F. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1908993 · Cited by 11
Targeted gene delivery systems for T-cell engineering
Wang, F., Huang, Y., Li, J., Zhou, W., & Wang, W. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00954-6 · Cited by 11
Shi, X., Bortolussi, G., Collaud, F., Brun, P.-R. L., ten Bloemendaal, L., Guerchet, N., de Waart, D. R., Sellier, P., Duijst, S., Veron, P., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101363 · Cited by 10
In vivo vectorization and delivery systems for gene therapies and RNA-based therapeutics in oncology
Vaiani, J. S., Broekgaarden, M., Coll, J., Sancey, L., & Busser, B. (2025) · Nanoscale · doi:10.1039/d4nr05371k · Cited by 12
Vono, M., del Rio, T., Magdaleno, E., Loll, N. R., Jarvis, P., Walter, C., Kikkawa, R., Mansfield, K., McBlane, F., Sirivelu, M. P., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101602 · Cited by 10
Zhang, F., Yan, X., Li, M., Hua, B., Xiao, X., Monahan, P. E., & Sun, J. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.355 · Cited by 10
An update of the current pharmacotherapeutic armamentarium for hemophilia A
Mahlangu, J. N. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1961742 · Cited by 10
Germini, F., Noronha, N., Philip, B. A., Olasupo, O. O., Pete, D., Navarro, T., Keepanasseril, A., Matino, D., de Wit, K., Parpia, S., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15723 · Cited by 10
Metadata
- Authors
- Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., & Pasi, K. J.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-28
- Volume
- 377
- Issue
- 26
- Pages
- 2519-2530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2775538622
- Cited by
- 694
- References
- 29
- Citations by year
- 2026: 33 · 2025: 59 · 2024: 65 · 2023: 57 · 2022: 95 · 2021: 81 · 2020: 112 · 2019: 90 · 2018: 95 · 2017: 5
- FWCI
- 63.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- BioMarin Pharmaceutical
- University Hospitals Birmingham NHS Foundation Trust
- National Institute for Health and Care Research
- University of Cambridge
- Imperial College London
- Imperial College Healthcare NHS Trust
- Barts Health NHS Trust
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, gene therapy, factor VIII, B-domain-deleted factor VIII, codon optimization, annualized bleeding rate, factor VIII activity, dose escalation, alanine aminotransferase elevation, chronic arthropathy, neutralizing antibodies
- MeSH terms
- Dependovirus, Adult, Antibodies, Viral, DNA, Viral, Factor VIII, Genetic Vectors, Hemophilia A, Hemorrhage, Humans, Infusions, Intravenous, Male, Genetic Therapy, Virus Shedding, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
